Rayaldee Approval History
- FDA approved: Yes (First approved June 17th, 2016)
- Brand name: Rayaldee
- Generic name: calcifediol
- Dosage form: Extended Release Capsules
- Company: OPKO Health, Inc.
- Treatment for: Secondary Hyperparathyroidism
Rayaldee (calcifediol) is a vitamin D3 analog indicated for the treatment of secondary hyperparathyroidism associated with vitamin D Insufficiency in stage 3-4 chronic kidney disease.
The safety and efficacy of Rayaldee was established from the results of two 26 week placebo controlled, double blind phase 3 trials of 213 patients with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels between 10 and 30 ng/mL. Data demonstrated that a larger proportion of patients achieved at least 30 percent reductions in plasma intact parathyroid hormone (iPTH) when treated with Rayaldee than with placebo. Vitamin D insufficiency was corrected in more than 80% of the patients receiving Rayaldee compared with less than 7% of subjects receiving placebo.
Rayaldee is an extended release capsule taken orally, once daily at bedtime. The most common side effects reported in clinical trials were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
Development History and FDA Approval Process for Rayaldee
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.